BCL2 and angioimmunoblastic T-cell lymphoma: To assess whether VLDP alters Bcl‐2 expression, lymphocytes from AILD patients and controls were treated with 5 IU/ml Proleukin for 18 h or 3 days and their Bcl‐2 expression was evaluated.